Predictors of Noncompliance in Patients With Schizophrenia
Open accessThe DOI matches its Crossref record.
Abstract
BACKGROUND: Around 50% of patients with schizophrenia do not fully comply with treatment, and noncompliance is linked to relapse, rehospitalization, poor outcome, and high economic costs. The health belief model views noncompliance as a decision made by the patient, arrived at after weighing the perceived risks and benefits of treatment. DATA SOURCES: A MEDLINE search for the years 1980-2002 using combinations of the keywords schizophrenia, compliance, adherence, antipsychotics, tolerability, and side effects was used to identify articles investigating the factors influencing compliance in schizophrenia. RESULTS: Many factors influence compliance, including those that affect patients' beliefs about their illness and the benefits of treatment (e.g., insight into illness, belief that medication can ameliorate symptoms), perceived costs of treatment (e.g., medication side effects), and barriers to treatment (e.g., ease of access to treatment, degree of family or social support). Medication side effects that are distressing to patients and linked to noncompliance include extrapyramidal side effects, neuroleptic dysphoria, akathisia, sexual dysfunction, and weight gain. Compliance can be improved by cognitive-behavioral therapies, such as compliance therapy, and other psychosocial interventions associated with improved social functioning and a lower risk of rehospitalization. Treatment adherence may also be improved by use of atypical antipsychotics with few perceived side effects. CONCLUSION: By considering the factors leading to noncompliance and adopting a comprehensive strategy for improving compliance, encompassing psychosocial intervention and optimum choice of medication, the management of schizophrenia could be greatly improved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Novick, D., Haro, J. M., Suarez, D., Perez, V., Dittmann, R. W., & Haddad, P. M. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.05.004 · Cited by 447
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369
García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000523 · Cited by 360
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Farmer, A. D., Strzelczyk, A., Finisguerra, A., Gourine, A. V., Gharabaghi, A., Hasan, A., Burger, A. M., Jaramillo, A. M., Mertens, A., Majid, A., et al. (2021) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.568051 · Cited by 355
The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal
Brissos, S., Veguilla, M. R., Taylor, D., & Balanzá-Martinez, V. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314540297 · Cited by 297
Sexual sequelae of general medical disorders
Basson, R., & Weijmar Schultz, W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60197-4 · Cited by 283
(2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.7090su1cj · Cited by 282
Social support and three-year symptom and admission outcomes for first episode psychosis.
Norman, R. M. G., Malla, A. K., Manchanda, R., Harricharan, R., Takhar, J., & Northcott, S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.05.006 · Cited by 219
Sykes, D. A., Moore, H., Stott, L., Holliday, N., Javitch, J. A., Lane, J. R., & Charlton, S. J. (2017) · Nature Communications · doi:10.1038/s41467-017-00716-z · Cited by 218
Cognitive-behavioral therapy for medication-resistant psychosis: A meta-analytic review
Burns, A. M. N., Erickson, D. H., & Brenner, C. A. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300213 · Cited by 199
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
Leslie, W. S., Hankey, C. R., & Lean, M. E. J. (2007) · QJM · doi:10.1093/qjmed/hcm044 · Cited by 173
Sexuality and Schizophrenia: A Review
Kelly, D. L., & Conley, R. R. (2004) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a007130 · Cited by 164
“Sexual dysfunction has been implicated as one of the major factors contributing to noncompliance with antipsychotic medications (Fleischhacker et al. 1994; Perkins 2002).”
BackgroundByerly, M., Suppes, T., Tran, Q.-V., & Baker, R. A. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815ac4e5 · Cited by 153
“Indeed, sexual dysfunction has been implicated as one of the factors contributing to noncompliance with antipsychotic medications.(43,44) Sexual dysfunction was ranked in the top 10 of subjectively ranked side effects with respect to the level of discomfort produced and regarded as worse than akinesia, tremor, rigidit…”
BackgroundVelligan, D. I., Weiden, P. J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R., & Docherty, J. P. (2010) · Journal of Psychiatric Practice · doi:10.1097/01.pra.0000367776.96012.ca · Cited by 134
Fontanella, C. A. (2008) · American Journal of Orthopsychiatry · doi:10.1037/a0012557 · Cited by 134
“Studies indicate that prior hospitalizations (Heflinger, Simpkins, & Foster, 2002; Pottick, Hansell, Gutterman, & Raskin-White, 1995) and/or noncompliance (Perkins, 2002) with treatment are strong Fontanella Page 3 Am J Orthopsychiatry.”
BackgroundDossenbach, M., Dyachkova, Y., Pirildar, S., Anders, M., Khalil, A., Araszkiewicz, A., Shakhnovich, T., Akram, A., Pecenak, J., McBride, M., et al. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.005 · Cited by 121
Czobor, P., Van Dorn, R. A., Citrome, L., Kahn, R. S., Fleischhacker, W. W., & Volavka, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.003 · Cited by 112
“In general, approximately 50% of schizophrenia patients do not fully adhere to treatment (Perkins, 2002).”
BackgroundDossenbach, M., Hodge, A., Anders, M., Molnár, B., Peciukaitiene, D., Krupka-Matuszczyk, I., Tatu, M., Bondar, V., Pecenak, J., Gorjanc, T., et al. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704005012 · Cited by 106
Kelly, D. L., & Conley, R. R. (2006) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2005.08.010 · Cited by 88
Dols, A., Sienaert, P., van Gerven, H., Schouws, S., Stevens, A., Kupka, R., & Stek, M. L. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836435e2 · Cited by 86
Read, J., & Williams, J. (2019) · Current Drug Safety · doi:10.2174/1574886314666190301152734 · Cited by 80
Drug interactions in dentistry
HERSH, E. V., & MOORE, P. A. (2004) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2004.0178 · Cited by 78
Konarzewska, B., Wołczyński, S., Szulc, A., Galińska, B., Popławska, R., & Waszkiewicz, N. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2008.08.015 · Cited by 70
“Sexual dysfunction has been implicated as a factor contributing to the non-adherence with antipsychotic medications (Perkins, 2002).”
BackgroundJaeger, S., Pfiffner, C., Weiser, P., Längle, G., Croissant, D., Schepp, W., Kilian, R., Becker, T., Eschweiler, G., & Steinert, T. (2013) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-013-0687-x · Cited by 63
Neurobiology of insight deficits in schizophrenia: An fMRI study
Shad, M. U., & Keshavan, M. S. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.04.021 · Cited by 52
Haro, J. M., Novick, D., Belger, M., & Jones, P. B. (2006) · European Psychiatry · doi:10.1016/j.eurpsy.2005.12.001 · Cited by 49
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Quality of life in schizophrenia spectrum disorders: Associations with insight and psychopathology
Margariti, M., Ploumpidis, D., Economou, M., Christodoulou, G. N., & Papadimitriou, G. N. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.11.016 · Cited by 41
Gomeni, R., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.141 · Cited by 38
De, R., Smith, E. C. C., Navagnanavel, J., Au, E., Maksyutynska, K., Papoulias, M., Singh, R., Panganiban, K. J., Humber, B., Mohr, G. H., et al. (2025) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13758 · Cited by 39
Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0132-7 · Cited by 35
Laffont, C. M., Gomeni, R., Zheng, B., Heidbreder, C., Fudala, P. J., & Nasser, A. F. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.366 · Cited by 26
Kavak Budak, F., & Yilmaz, E. (2019) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2019.100949 · Cited by 19
Redefining Medication Adherence in the Treatment of Schizophrenia
Weiden, P. J. (2016) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2016.01.004 · Cited by 16
Meola, T. R., Kamath, S., Elz, A. S., Prestidge, C. A., Wignall, A., & Joyce, P. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114453 · Cited by 10
Metadata
- Authors
- Perkins, D. O.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-12-15
- Volume
- 63
- Issue
- 12
- Pages
- 1121-1128
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2047151451
- Cited by
- 544
- References
- 0
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.